Liseva Bio Information

Liseva Bio is developing NK cell therapy for ovarian cancer and other solid tumors where immune cell therapy has historically failed. The problem is fundamental: when natural killer cells are sent into a tumor to fight cancer, the hostile tumor environment destroys them before they can do their job. It's like sending firefighters into a burning building without protective gear. Our platform arms NK cells with the protection they need to survive inside tumors and keep fighting. In laboratory testing, our armored NK cells killed 46 times more cancer cells than standard NK cells under stress conditions relevant to the solid tumor microenvironment — and the advantage persists through freezing and thawing, enabling off-the-shelf manufacturing and delivery to patients anywhere. Our lead indication is platinum-resistant high-grade serous ovarian cancer, where patients who have exhausted standard treatment options urgently need a new approach. Our delivery strategy concentrates NK cells directly at the disease site, giving them the best possible chance to find and fight cancer. No gene editing required. Off-the-shelf manufacturing. IP protected with multiple provisional patents filed. Liseva Bio is a Rhode Island-based company supported by the Rhode Island Life Science Hub, founded by Dr. Joseph Hoffmann, PhD, a cell therapy scientist with over a decade of experience including senior roles at Vertex Pharmaceuticals. #OvarianCancer #NKCellTherapy #CellTherapy #CancerImmunotherapy #Biotechnology #RhodeIsland